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Abstract 
 
Context. Toxicity from use of synthetic cannabinoid receptor agonists (SCRAs) has been 
encountered increasingly frequently in many countries.   
Objective. To characterise presentation rates, demographic profiles and reported clinical 
features for users of SCRAs referred by health professionals in the United Kingdom to the 
National Poisons Information Service (NPIS), to compare reported toxicity between 
commonly used branded products, and to examine the impact of legal control measures on 
enquiry numbers. 
Methods. NPIS telephone enquiry records were searched for SCRA-related terms for the 8 
year period 1st January 2007 to 31st December 2014, consolidating multiple enquiries about 
the same case into a single record. Demographic data, reported exposure details, clinical 
features and poisoning severity were analysed, excluding cases where SCRA exposure was 
unlikely.  
Results. Enquiries to the NPIS were made concerning 510 individuals relating to probable 
SCRA use, with annual numbers increasing year on year. Most patients were male (80.8%) 
and <25 years old (65.1%). Common clinical features reported in the 433 (84.9%) patients 
reporting SCRA use without other substances included tachycardia (n = 73, 16.9%), reduced 
level of consciousness (n = 70, 16.2%), agitation or aggression (n = 45, 10.4%), vomiting (n 
= 30, 6.9%), dizziness (n = 26, 6.0%), confusion (n= 21, 4.8%), mydriasis (n = 20, 4.6%) and 
hallucinations (n = 20, 4.6%). The Maximum Poisoning Severity Score (PSS) indicated 
severe toxicity in 36 cases (8.3%). Legal control of ‘second generation’ SCRAs did not affect 
the rate of growth in enquiry numbers or the proportion with severe toxicity. The three most 
commonly reported products were ‘Black Mamba’ (n= 88, 20.3%), ‘Pandora’s Box’ (n= 65, 
15%) and ‘Clockwork Orange’ (n= 27, 6.2%). Neurological and general features were 
recorded more often with ‘Clockwork Orange’ than for ‘Black Mamba’ and ‘Pandora’s Box’, 
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but moderate or severe toxicity was significantly less common after reported use of this 
product. 
Conclusions. Enquiries about SCRA-related toxicity have become increasingly frequent in 
the UK in spite of legal controls and commonly involve younger males. Differences in the 
patterns of toxicity associated with different branded preparations may occur, although 
further work with larger patient numbers is needed to confirm this.  
 
 
 
Introduction 
Synthetic cannabinoid receptor agonists (SCRAs) are increasingly encountered as 
alternatives to cannabis. [1, 2] They are incorporated into many branded products currently 
available for purchase from ‘head-shops’ or via the internet. [1] These usually consist of 
plant based material to which SCRAs are added. [1, 3] 
SCRAs are synthetic modifications to ∆9-tetrahydrocannabinol (∆9-THC), the principal 
phytocannabinoid occurring in the cannabis plant (Figure 1). [4, 5] Like ∆9-THC, they are 
cannabinoid receptor agonists [6] and have similar pharmacological effects. [7, 8]  However, 
unlike the partial agonist ∆9-THC [1], several SCRAs, such as HU-210 and UR-144, are full 
cannabinoid receptor agonists [9, 10]  and many exhibit an increased binding affinity for both 
cannabinoid receptors (CB1 and CB2) compared to ∆9-THC. [4, 5, 7, 11, 12] This may explain 
in part the altered pattern of clinical features and increased severity of toxic effects reported 
after SCRA use such as encephalopathy and seizure, [13] myocardial infarction, [14] acute 
kidney injury [15] and extreme psychiatric effects. [16] Some SCRAs are also weak 
monoamine oxidase inhibitors, which may explain apparent serotoninergic effects. [17] Batch 
to batch and within product variability in SCRA content [18, 19] and the presence of more 
than one SCRA in some products [20] may also contribute to unpredictable toxic effects. 
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There is evidence of a significant increase in the number of SCRA users and associated 
adverse health effects in recent years. [21, 22, 23] The number of calls to poisons centres in 
the United States (US) indicates a 229% increase in 2015 compared to 2014. [21] Legal 
measures to control their use have been taken in many countries. In the United Kingdom 
(UK), early so-called ‘first generation’ SCRAs, including JWH-018, were controlled in 
December 2009 [24] and further legislation to control so-called ‘second generation’ products, 
including AM2201 and UR-144, was enacted in February 2013. [25] However, subsequent 
manipulation of the chemical structure of these compounds has resulted in a further (‘third’) 
generation of SCRAs that are not currently legally controlled in the UK including PB-22, 5F-
PB-22, STS-135 and 5F-AKB-48. [26] Further legislation is planned, but this will be based on 
a revised generic description rather than chemical structure. [26] 
While there is some published evidence of the increasing use and toxicity of SCRAs, limited 
evidence has been published examining the impacts of legal controls on presentations with 
toxicity or comparing toxicity between individual SCRAs and SCRA products. This study was 
therefore performed to characterise the patterns of referrals with SCRA-related toxicity to the 
UK poisons centres, describe the features of toxicity encountered, compare reported clinical 
features and severity of poisoning between the most commonly used products and examine 
the impact of legal control measures on enquiry numbers. 
Methods 
The study used fully anonymised data collected routinely during telephone enquiries to the 
National Poison Information Service (NPIS). In the UK, use of such data does not require 
ethical approval. The NPIS, commissioned by the Health Protection Agency until April 2013 
and then by Public Health England, provides clinical advice to health professionals across 
the UK about the management of toxicity, including toxic effects from legal and illegal 
recreational drugs. The service is provided by four units located in Newcastle, Edinburgh, 
Cardiff and Birmingham that work together to provide an integrated 24 hour service. Health 
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professionals can access poisons information on-line via the NPIS’s TOXBASE website. 
Additional telephone advice can be provided by specialists in poisons information who are 
supported by a consultant clinical toxicologist as required for complex and severe cases. 
For this study a list of 378 possible search terms was compiled to capture the names of 
SCRAs and SCRA-containing products. This was done by searching for product terms 
associated with SCRAs in the academic literature and the internet including websites 
provided for drug users and by internet drug suppliers. We also used the website of the 
Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) project, [27] 
which was launched in September 2013 and provides details of the analytical content of 
products sent by drug users from across the UK. 
Individual SCRAs were described by generation according to how they were affected by UK 
drugs legislation, with first generation products being those controlled in December 2009, 
second generation products those additional SCRAs controlled in February 2013 and third 
generation products those remaining uncontrolled after that date. Note that classification by 
generation may vary between countries because of international differences in the timing 
and detail of drug control measures. 
All telephone enquiries containing a reference to any of the search terms at any point in the 
clinical record were extracted for the 8 year period 1st January 2007 to 31st December 2014. 
These were then reviewed manually and those with no clear evidence of SCRA use were 
excluded. For the remaining records, multiple enquiries about the same case were 
consolidated into a single record, from which the details extracted included the source and 
date of the enquiry, the age and sex of the patient, the reported exposure substance and 
route, the recorded clinical features and available laboratory results. For each case the 
maximum Poisoning Severity Score (PSS), as developed by the World Health Organisation, 
International Programme on Chemical Safety, Commission of European Union and 
European Association of Poison Centres and Clinical Toxicologists [28] was also obtained, if 
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recorded. This validated scale grades the severity of poisoning from 0 (No symptoms or 
signs related to poisoning) to 4 (death as a result of poisoning). 
To minimise the effects of other recreational or pharmaceutical agents on clinical features 
and severity of toxicity of SCRA, patients who reported using other agents simultaneously 
were identified (co-use group) and excluded from analyses of clinical features and poisoning 
severity.  
 
Chi-square tests were used to compare the severity of poisoning among the most commonly 
used products. The severity of poisoning with SCRA products overall was also compared 
before and after the second (February 2013) modification of the Misuse of Drug Act. 
Results 
The search terms that might indicate SCRA exposure generated 1196 entries. After removal 
of those where SCRA exposure was unlikely and consolidation of multiple enquiries about 
the same case into a single record, 510 cases of probable SCRA use were identified during 
the study period, with hospitals (391, 76.7%) and paramedics (63, 12.3%) the most common 
source of enquiries. Other sources of enquiries included general practitioners (GPs), staff of 
National Health Service (NHS) patient helplines (NHS 111, NHS 24 or NHS Direct) and the 
Police. There were very few cases reported prior to 2011, but enquiries increased rapidly 
between 2011 and 2014 (Figure 2). Isolated SCRA use was reported in most cases (464, 
91.0%), but in 46 (9.0 %) there was co-use with other substances, most commonly Central 
Nervous System (CNS) depressants such as ethanol, opioids or benzodiazepines. 
For the 494 enquiries where the gender was known, 399 (80.8%) were male. The median 
age of SCRA users was 21 years (range 12-78 years, interquartile range 16-29 years).  
Excluding 24 cases where the age was not documented, 306 (65.1%) were below the age of 
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25 and 173 (36.8%) below the age of 18 years. Three 12 year old males were the youngest 
SCRA users reported to the NPIS. (Figure 3) 
A maximum PSS was recorded in 479 (93.9%) referrals (Table 1); in the 433 SCRA users 
without substance co-use who had a maximum PSS recorded, this was 0 (no toxicity) in 37 
(8.5%), 1 (minor) in 234 (54.0%), 2 (moderate) in 126 (29.1%) and 3 (severe) in 36 cases 
(8.3%). There was one reported fatal case resulting from head trauma after a fall, although 
there was inadequate information to conclude that SCRA toxicity was the direct cause of 
death. Although the co-use group was excluded from this analysis, there was no significant 
difference in maximum PSS between those using SCRAs with and without other substances 
(p > 0.05). The most common clinical features reported in these SCRA users without 
substance co-use were tachycardia, reduced level of consciousness, agitation or 
aggression, vomiting, dizziness, confusion, mydriasis and hallucinations (Table 2). 
There were inadequate numbers of enquiries before and soon after the December 2009 
modification to the Misuse of Drugs Act that controlled first generation SCRAs to assess the 
impact of this. Total enquiry numbers continued to increase in spite of the control of second 
generation SCRAs in February 2013. (Figure 2) and there was no significant difference in 
the severity of toxicity between those presenting before and after this date (p > 0.05). 
Most reported SCRA use involved the use of branded products. The five most commonly 
reported, with or without co-use of other substances, were ‘Black Mamba’ (n=107, 21.0%) 
‘Pandora’s Box’ (n=73, 14.3%), ‘Clockwork Orange’ (n=34, 6.7%), ‘Cherry Bomb’ (n=27, 
5.3%) and ‘Annihilation’ (n=19, 3.7%). Enquiries involving ‘Annihilation’ were largely confined 
to the period before control of second generation SCRAs, while those associated with 
‘Pandora’s Box’, ‘Clockwork Orange’ and ‘Cherry Bomb’ emerged subsequently. For ‘Black 
Mamba’, there was a reduction in telephone enquiries around the time of 2nd generation 
SCRA control but a subsequent growth in enquiry numbers to a second peak in the 1st 
quarter of 2014 (Figure 4). 
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Poisoning severity scores were compared for isolated use of the three most common SCRA 
products (Table 4). No significant differences were observed comparing ‘Black Mamba’ with 
‘Pandora’s Box’ (p > 0.05). ‘Clockwork Orange’ was associated with significantly lower 
poisons severity scores (p = 0.01) compared to ‘Pandora’s Box’, but the total numbers of 
enquiries were small.  A higher proportion of cases involving neurological or general features 
in ‘Clockwork Orange’ users compared to ‘Pandora’s Box’ or ‘Black Mamba’ was observed. 
 
 
Discussion 
These data demonstrate a substantial recent increase in poisons centre enquiries related to 
SCRA use in the UK, especially between early 2011 and late 2013. These predominantly 
involve young males, as previously reported in other countries. [30] It is a particular concern 
that over a third of enquiries involved people less than 18 years of age. 
The most common reported clinical features in SCRA users who did not report concurrent 
use of other substances were tachycardia, reduced level of consciousness, agitation or 
aggression, vomiting and dizziness. Confusion, hallucinations, chest pain, blood pressure 
disturbances, and seizures were also reported. These clinical features are consistent with 
reports from other international studies, [29-34] although several were less commonly 
documented in this UK case series; this may arise from incomplete reporting of clinical 
details in NPIS enquiries. While cannabis toxicity presenting to emergency departments was 
associated with agitation or aggression (23%), psychosis (20%), anxiety (20%) or vomiting 
(17%) in one case series, [35] several clinical features associated with SCRA use are not 
typical of cannabis exposure, including bradycardia and seizures. Consistent with earlier 
reports, [15, 34, 36] renal impairment, as evidenced by elevated plasma creatinine, was also 
observed in a small proportion of cases. 
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During the data collection period for this study there were two modifications made to the 
Misuse of Drugs Act to control SCRAs. The data presented here cannot be used to evaluate 
first generation control in December 2009 as there were very few NPIS enquiries around the 
time of that change. However, there was a substantial increase in SCRA use in the second 
half of 2011 in spite of this earlier legislation. There is no suggestion that second generation 
control in February 2013 affected the growth in SCRA-related enquiries overall, although 
these are observational data and the rate of growth in enquiries in the absence of legal 
control cannot be estimated. Also, the impact of associated publicity on poisons centre 
enquiries is difficult to estimate, although unlikely to be major for telephone enquiries made  
by health professionals. Previous research has suggested that first generation control in the 
UK had a limited impact on internet SCRA sales, with continued supply of SCRAs controlled 
under the legislation, as well as the emergence of newer uncontrolled compounds. [37] 
Legislation in the Unites States, Ireland and Australia restricting the sale of SCRAs, 
however, was associated with reductions in SCRA-related enquiries to poisons centres. [31, 
38, 39]  
Although total numbers of enquiries continued to increase, there were changes to the 
patterns of branded SCRA-containing products involved in enquiries (Figure 4). Those 
relating to ‘Annihilation’ fell after the introduction of second generation controls. According to 
Drugwatch, analysis of this product identified the ‘second generation’ cannabinoids MAM-
2201 and UR-144. [40] Enquiries relating to ‘Pandora’s Box’, ‘Clockwork Orange’ and 
‘Cherry Bomb’ increased after second generation control. Analysis of products submitted to 
WEDINOS during 2014 has shown these to contain the 3rd generation SCRAs BB-22, 5F-
PB-22 and 5F-AKB48. [27] For ‘Black Mamba,’  the number of cases fell after the time of 
legal control of second generation SCRAs and none were encountered during the 2nd 
quarter of 2013. However, this product reappeared in the second half of 2013 and related 
poison centre enquiries gradually increased after that (Figure 4). Early samples of ‘Black 
Mamba’ contained the second generation SCRA AM-2201, [26] but more recent samples 
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analysed in 2014 by WEDINOS have contained the currently uncontrolled third generation 
SCRAs 5F-PB-22 and 5F-AKB-48, although there was also one sample containing AM-2201. 
[27] This suggests that, in response to legal control, suppliers may change the products 
being sold or the active constituents of popular branded products so that these are no longer 
affected by the updated legislation.  
It is important to consider not only the numbers of enquiries, but also their severity. Legal 
control could reduce the frequency of severe episodes by reducing availability of substances 
shown to be associated with acute harms. On the other hand, control of established 
substances may encourage users to move to newer SCRAs for which there is less 
experience of use and where toxicity may be greater. We therefore examined the patterns of 
poisons severity scores by year and also before and after control of second generation 
products, but found no time-related differences in the proportion of enquiries associated with 
moderate or severe poisoning (Table 3).  
We also compared clinical features and severity of poisoning between the three most 
commonly encountered SCRA-containing branded products. Samples of all three products 
commonly contain 5F-PB-22 and 5F-AKB48, [27] but differences in toxicity could arise from 
differences in dose as there is no quantitative information available on their SCRA content. 
Exposures to ‘Clockwork Orange’ were associated with a higher proportion of general and 
neurological features (Table 4), but moderate or severe toxicity was less common with this 
product. However, the numbers of enquiries for each product, especially ‘Clockwork 
Orange’, were modest so the reliability of these findings is uncertain and further monitoring is 
needed. 
Use of information collected during poisons centre enquiries has important limitations that 
need to be taken into account in interpretation. The number of enquiries does not reflect 
directly the number of clinical exposures or hospital presentations as not all of these will be 
discussed with a poisons centre. Health professionals may rely on other sources for advice, 
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including the NPIS poisons information database TOXBASE, restricting telephone enquiries 
to more severely poisoned or unusual cases. Conversely, several enquiries may be received 
about the same case and identification and consolidation of duplicated information using 
anonymised records may not always be possible.  Clinical features reported during enquiries 
are often incomplete because only the data needed to answer the enquiry may be given. 
Although information on other substances used is sought, accurate information may not be 
reported by the patient or the enquirer, resulting in an underestimate of the numbers using 
multiple substances. Also, clinical features that occur after the enquiry has been made are 
usually not captured. Although follow up is attempted, especially for severe cases, this is 
often unsuccessful and the final outcome may not be known. This may explain the lower 
incidence of several clinical features in this series compared with others.  
Accurate identification of the chemicals involved in episodes of toxicity is challenging 
because analytical confirmation is not performed in routine clinical practice. This is a 
particular problem for SCRAs in view of the large range of branded products involved. The 
chemical content of these can change with time, [35] therefore comparison using cases of 
exposure across time to brands that appear similar can be misleading.  
Although analysis of clinical features and severity excluded those admitting concurrent use 
of other substances, the possibility that these may be involved and might have contributed to 
clinical features in some of these cases cannot be excluded. 
Conclusions 
NPIS data indicate that cases of toxicity associated with SCRA use have increased in the 
UK and most commonly involve younger males. Some reported clinical features differ from 
those associated with cannabis use and severe effects may occur, as previously reported. 
No clear evidence of an effect of legal control on enquiry numbers or severity was found. 
Further research is needed to characterise possible differences in toxicity between different 
branded products.  
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Table 1: Maximum Poisoning Severity Scores (Max PSS) for cases of sole SCRA* use  
*Synthetic Cannabinoid Agonist Receptors, **Where known 
 
 
 
 
 
 
 
 
 
 Year  
Max PSS 
n, (%**) 
2009 2010 2011 2012 2013 2014 Total 
None (0)   0 0 0 9  
(12.5%) 
9    
(6.0%) 
19  
(9.8%) 
37  
(8.5%) 
Minor (1) 2  
(66.7%) 
2 
(100%) 
4   
(33.3%) 
39 
(54.2%) 
88 
(58.7%) 
99 
(51.0%) 
234 
(54.0%) 
Moderate (2) 1  
(33.3%) 
0 5   
(41.7%) 
19 
(26.4%) 
40 
(26.7%) 
61 
(31.4%) 
126 
(29.1%) 
Severe (3) 0 0 3   
(25.0%) 
5    
(6.9%) 
13  
(8.7%) 
15  
(7.7%) 
36 
(8.3%) 
Total (Max 
PSS recorded) 
3 2 12 72 150 194 433 
Max PSS 
unknown 
 1  0 0 1     18  11  31  
Total 4 2 12 73 168 205 464 
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Table 2: Clinical Features reported to the NPIS* for Synthetic Cannabinoid Receptor Agonist 
users (in ≥5 reported cases) 
 
Clinical Features 
All patients  
(n=510) 
Isolated SCRAs use  
(n=433) 
 n % n % 
General  33 6.5 % 28 6.5% 
Abnormal Sweating 8 1.6% 7 1.6% 
Malaise 10 2.0% 9 2.1% 
Other 15 2.9% 11 2.5% 
Gastrointestinal 64 12.5% 57 13.2% 
Vomiting 34 6.7% 30 6.9% 
Nausea 16 3.1% 16 3.7% 
Abdominal Pain 8 1.6% 7 1.6% 
Dry Mouth 6 1.2% 5 1.2% 
Neurological 165 32.4% 160 37.0% 
Reduced level of 
consciousness 
87 17.1% 70 16.2% 
Mydriasis 24 4.7% 20 4.6% 
Headache 16 3.1% 15 3.5% 
Seizure 9 1.8% 7 1.6% 
Clonus 6 1.2% 6 1.4% 
Cardiorespiratory 210 41.2% 191 44.1% 
Tachycardia (>100) 81 15.9% 73 16.9% 
Dizziness 28 5.5% 26 6.0% 
Chest Pain 20 3.9% 20 4.6% 
Hypotension (SBP<80) 16 3.1% 15 3.5% 
Palpitations 14 2.7% 13 3.0% 
Bradycardia (<60) 9 1.8% 8 1.8% 
Hypertension (SBP>160) 9 1.8% 7 1.6% 
Abnormal ECG 9 1.8% 5 1.2% 
Arrhythmia 6 1.2% 6 1.4% 
Psychiatric 121 23.7% 111 25.6% 
Agitation/Aggression 50 9.8% 45 10.4% 
Confusion 23 4.5% 21 4.8% 
Hallucination 22 4.3% 20 4.6% 
Paranoid 
Ideation/Psychosis 
6 1.2% 6 1.4% 
Anxiety 6 1.2% 5 1.2% 
Speech Disorder 6 1.2% 6 1.4% 
Lab Findings 24 4.7% 16 3.7% 
Acidosis/Acidosis Lactic 14 2.7% 10 2.3% 
Elevated Creatinine  10 2.0% 6 1.4% 
* National Poisons Information Service  
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Table 3: Maximum Poisoning Severity Scores for sole SCRA* use before and after 
implementation of second generation SCRA control in February 2013. No significant 
difference in the severity of toxicity was found between two groups (P > 0.05). 
Maximum PSS  
n,  (%) 
   0     
(None) 
1     
(Minor) 
2  
(Moderate) 
3  
(Severe) 
 
Total 
Jan 2010- Feb 2013 11  
(10.9%) 
51  
(50.5%) 
30  
(29.7%) 
9  
(8.9%) 
 
101 
After Feb 2013 26  
(7.9%) 
181  
(55.0%) 
95  
(28.9%) 
27  
(8.2%) 
 
329 
Total 37  
(8.6%) 
 
232  
(54.0%) 
125  
(29.1%) 
36  
(8.4%) 
430 
* Synthetic Cannabinoid Receptor Agonist 
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Table 4: Clinical features and Maximum Poisoning Severity Scores (PSS) for the three most 
commonly used Synthetic Cannabinoid Receptor Agonist products, without reported co-use 
of other substances. 
 
 Black Mamba 
n=88 
Pandora’s Box 
n=65 
Clockwork 
Orange 
n=27 
Clinical features    
Cardiovascular 36 (40.9%) 28 (43.1%) 12 (44.4%) 
Neurological 19 (21.6%) 12 (18.5%) 12 (44.4%) 
Psychiatric 25 (28.4%) 17 (26.2%) 8 (29.6%) 
Gastrointestinal 7 (8.0%) 9 (13.8%) 2 (7.4%) 
General 5 (5.7%) 2 (3.1%) 6 (22.2%) 
Lab findings 7 (8.0%) 4 (6.2%) 1 (3.7%) 
 
Maximum PSS 
   
  None (0)   7 (8.0%) 7 (10.8%) 1 (3.7%) 
  Minor (1) 53 (60.2%) 31 (47.7%) 23 (85.2%) 
  Moderate (2) 22 (25.0%) 22 (33.8%) 3 (11.1%) 
  Severe (3) 6 (6.8%) 5 (7.7%) 0 (0%) 
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Figure 1. Chemical structure of Δ9-Tetrahydrocannabinol (THC) and three examples 
of synthetic cannabinoid receptor agonists.  
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Figure 2: Quarterly numbers of reported cases of synthetic cannabinoid receptor 
agonist (SCRA) related toxicity referred to the National Poisons Information Service 
(NPIS) from 2007 to 2014.  Arrows indicate the timing of legal control of first and 
second generation SCRAs (Dec 2009 and Feb 2013). 
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Figure 3: Age (in year) and gender distribution of synthetic cannabinoid receptor 
agonist users. 
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Figure 4: Quarterly numbers of reported cases relating to the 5 synthetic 
cannabinoid receptor agonist (SCRA) products most commonly reported to the 
National Poisons Information Service between 2009 and 2014.  Arrows indicate the 
0
2
4
6
8
10
12
14
16
18
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
Ja
n
-M
ar
A
p
r-
Ju
n
Ju
l-
Se
p
O
ct
-D
ec
2009 2010 2011 2012 2013 2014
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Black Mamba Pandora's Box Clockwork Orange Cherry Bomb Annihilation
1
st
 le
gi
sl
at
io
n
2
n
d
 le
gi
sl
at
io
n
24 
 
timing of legal control of first and second generation SCRAs (December 2009 and 
February 2013). 
 
 
